Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/04/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 16/04/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.41B | |
| -1.02% | -1.47% | +24.52% | +78.33% | 59.26B | |
| +0.96% | -0.39% | +4.54% | +34.84% | 47.14B | |
| -3.02% | -5.20% | +27.94% | +32.51% | 42.91B | |
| +0.31% | +3.02% | +348.95% | +643.82% | 44.13B | |
| -1.96% | -0.33% | +7.04% | +99.46% | 40.79B | |
| +3.32% | +3.49% | +10.10% | +51.23% | 30.77B | |
| -2.68% | +2.92% | +29.63% | +22.72% | 29.31B | |
| -4.86% | -10.66% | -26.27% | +330.06% | 23.71B | |
| Average | -0.48% | -0.52% | +52.87% | +154.13% | 43.6B | |
| Weighted average by Cap. | +0.02% | -0.32% | +58.05% | +145.82% |
Employees
51
